LONG-TERM RISK MANAGEMENT IN ARTERIAL HYPERTENSION: FOCUS ON PERINDOPRIL


Cite item

Full Text

Abstract

Experience of clinical trials with perindorpil in cardiovascular and renal risk control is analyzed.

About the authors

Viktor Viktorovich Fomin

V Fomin

References

  1. Morgan TO, Anderson DI, Maclnnis RJ. ACE inhibitors, beta-blockers, calcium blockers and diuretics for the control of systolic hypertension. Am J Hypertens 2001;14:241-47.
  2. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995;8:189-92.
  3. Комитет экспертов РМОАГ / ВНОК. Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ/ВНОК. Системные гипертензии 2010. № 3. C. 5-26.
  4. Dahlof B, Sever P, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.
  5. The CAFÉ Investigators. Differential impact of blood-pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006;113(9):1213-25.
  6. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
  7. Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24(6):1201-208.
  8. Arima H, Hart RG, Colman S, et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005;36(10):2164-69.
  9. Berthet K, Neal BC, Chalmers JP, et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004;13(1):7-13.
  10. Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004;35(1):116-21.
  11. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163(9):1069-75.
  12. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005;112(11):1644-50.
  13. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. PROGRESS Collaborative Group. Eur Heart J 2003;24(5):475-84.
  14. Campbell DJ, Woodward M, Chalmers JP, et al. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. J Hypertens 2007;25(3):699-705.
  15. Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pressure lowering on cardiovascular outcomes in normal eight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension 2010;55(5):1193-98.
  16. Andrejak M, Zannad F, Laville M, et al. Evaluation of different approaches to the treatment of arterial hypertension: combination treatment with low dose perindopril/indapamide versus sequential treatment of stepped-dose treatment. Therapie 2003;58(4):351-52.
  17. Chanudet X, De Champvallins M. Antihypertensive efficacy and tolerability of low-dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. Int J Clin Pract 2001;55(4):233-39.
  18. Mourad JJ, Nguyen V, Lopez-Sublet M, et al. Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: results of the OPTIMAX trial. Vasc. Health Risk Manag 2007;3(1):173-80.
  19. Mourad JJ, Waeber B, Zannad F, et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004;22(12):2379-86.
  20. Libhaber EN, Libhaber CD, Candy GP, et al. Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry. Am J Hypertens 2004;17(5):428-32.
  21. Gosse P, Dubourg O, Gueret P, et al. Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mgcombination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. J Hum Hypertens 2002;16(9):653-59.
  22. ADVANCE Collaborative Group. Study rationale and design of ADVANCE: action in diabetes and vascular disease preterax and diamicron MR controlled evaluation. Diabetologia 2001;44:1118-20.
  23. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829-40.
  24. Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003;41:1063-71.
  25. Heerspink HJ, Ninomiya T, Perkovic V, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010;31(23):2888-96.
  26. Ionescu DD. PREFER Investigators. Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study. Clin Drug Investig 2009;29(12):767-76.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies